October 29, 2020 | ~Home Feature| Media Coverage
Castle Creek Biosciences’ D-Fi To Be Manufactured At In-House cGMP
Read MoreOctober 28, 2020 | ~Home Feature| Press Release
Company manufacturing and distributing D-Fi at in-house, cGMP commercial-scale facility in greater Philadelphia area
Read MoreOctober 20, 2020 | ~Home Feature| Media Coverage
First Patient Treated in Trial Testing FCX-013 Gene Therapy for Localized Scleroderma
Read MoreOctober 15, 2020 | ~Home Feature| Press Release
Study targets a chronic autoimmune skin disorder affecting approximately 50,000 patients in the U.S.
Read MoreFebruary 29, 2020 | ~Home Feature| Media Coverage
NextUp: “The Company Using Gene Therapy to Cure Rare Skin Conditions” John Maslowski, CEO, Castle Creek Biosciences
Read More